Quadruple Misfolded Proteins in Older Adults

- Posted by admin in English

In this cohort study, Shama Karanth and colleagues from University of Kentucky, Lexington, investigated quadruple misfolded proteins and other proteinopathy combinations in a cohort of 375 deceased individuals with autopsy data in the University of Kentucky Alzheimer Disease Center (UK-ADC).

At least 3 proteinopathies were observed in 50% of brains.

In addition, quadruple misfolded proteins were associated with severe cognitive impairment at least 12 years before death.

Participants with 3 proteinopathies tended to have poorer global cognition earlier than with the presence of only tau and Aβ and were likely to have higher Braak stages.

Previous studies have reported cognitive decline associated with the presence of mixed pathologies, with study to study differences in methods and proteinopathies, the assessment and inclusion of cerebrovascular pathologies, and hippocampal sclerosis. In the present sample, as in other community based cohorts, FTLD in old age was rare (with an estimated incidence of 8.9 of 100 000 in individuals aged 60 to 69 years; no incidence data are available for older age groups) and was not found in brains of individuals who began follow up with normal cognition.

Individuals with FTLD-TDP-43 with data in the UK-ADC Brain Bank were recruited from a dementia clinic. The scientists excluded 6 individuals with FTLD-TDP-43 in the study; none had the quadruple misfolded proteins phenotype. No discernible overlap in any FTLD feature was observed in these individuals other than presence of TDP-43 proteinopathy, which is now detected in many different neurological diseases outside of the amyotrophic lateral sclerosis–FTLD spectrum.

Cognitive impairment was associated with quadruple misfolded proteins at autopsy, with 89.1% of participants developing dementia and some experiencing profound impairment up to 12 years before death. This finding suggests that quadruple misfolded proteins occur before end stage Alzheimer disease neuropathological change (ie, before high Braak stage).

Consistent with this hypothesis, the mild cognitive impairment to dementia transition was, on average, fastest in the quadruple misfolded proteins group. Estimation of the group cognitive trajectories was aided by the relatively long followup (mean duration of 10.4 years).

These data provide the basis for a novel hypothesis that quadruple misfolded proteins have a more aggressive phenotype from the early stages of the disease rather than accruing additional pathologies only after Alzheimer disease neuropathological change has progressed to high levels. About 10% of these participants died with normal cognition, and previous research has shown quadruple misfolded proteins were present in persons with apparently normal cognition. In the present study, all individuals with quadruple misfolded proteins who had normal cognition at the last visit before death had lower Braak NFT stages (I to III), had no APOEε4 allele, and were predominantly male (4 of 5 participants).

These individuals may represent an early stage of quadruple misfolded proteins, but there are complexities: clinical presentation of proteinopathy combinations may be cohort specific and depend on other currently unknown factors. Older cohorts that survive into advanced old age, like those in the UK-ADC study, may be more likely to experience multiple proteinopathies than younger cohorts. As previously described, APOE appeared to be associated with multiple proteinopathies in this study, particularly those proteinopathy combinations including Aβ plaques. Carriers of APOEε allele not only had increased odds of tau and Aβ, an expected result, but also had higher odds of tau, Aβ, and αsynuclein; tau, Aβ, and TDP-43; and quadruple misfolded proteins.

Unlike previous studies, this study did not find evidence that the ε4 allele was associated with tau or TDP-43 in the absence of Aβ, but the sample size was relatively small. The temporality of protein misfolding may play a clinically important and differentiating role in disease progression.

Autopsy data, although cross-sectional by nature, are compatible with the hypothesis that Aβ aggregates precede, and perhaps stimulate or exacerbate, the widespread misfolding of tau, TDP-43, and α-synuclein. These results suggest that TDP-43 pathology may be associated with poor global cognition.

The presence of multiple proteinopathies, particularly the quadruple misfolded proteins phenotype, appeared to have been associated with the cognitive decline in deceased individuals who participated in a longitudinal community based study at the UK-ADC.

These observations have potentially significant implications for clinical practice and public health, given that strategies to prevent or manage AD dementia may be complicated by the unrecognized presence of multiple additional neuropathologies.

Two epigenetic regulators interfere with healthy aging

- Posted by admin in English

It has long been assumed that lifespan and health are strongly correlated, but although there has been an overall increase in human life expectancy in recent decades, it is too often accompanied by deterioration of health.

A new study published on February 26 in Nature shows the influence of two epigenetic regulators on aging. Scientists led by Jie Yuan from the Chinese Academy of Sciences in Shanghai have studied the BAZ-2 and SET-6 proteins in Caenorhabditis elegans worms, which are orthologs of the human proteins BAZ2B and EHMT1.

Through genome-wide RNA-interference-based screening of genes that regulate behavioral deterioration in aging C. elegans, the researchers identified 59 genes as potential health modulators during aging. Essentially the proteins expressed by these genes, read and write epigenetic signals.

Among these modulators, they found that a neuronal epigenetic reader, BAZ-2, and a neuronal histone SET-6, accelerate the deterioration of the behavior of C. elegans by reducing the mitochondrial function, and repressing the expression of the encoded mitochondrial proteins. in the cell nucleus.

The researchers found that the levels of the two proteins increase with age in C. elegans and mice, which in turn attenuates the expression of genes involved in mitochondrial function.

BAZ-2 and SET-6 are complementary epigenetic mechanisms. SET-6 is an "epigenetic writer" and BAZ-2 is an "epigenetic reader" which recognizes modified histones and recruits transcriptional regulators.

Histones are proteins located in the nucleus of eukaryotic cells. They are the main protein components of chromosomes. They are closely associated with DNA and allow their compaction, but they also modify the expression of proteins by various epigenetic mechanisms known as the "histone code".

enter image description here Source Wikipedia.

How do BAZ-2 and SET-6 accelerate aging? The researchers found that the two proteins bind together to the promoter regions of more than 2,000 genes, and decrease their expression via methylation of histones. Among these target genes are many mitochondrial genes encoded nuclear. By suppressing the expression of these genes, BAZ-2 and SET-6 reduce oxygen consumption and ATP production, and decrease the critical stress responses that maintain mitochondrial proteostasis. The resulting metabolic slowdown discourages the worms from assimilating their food and they mate less.

This mechanism is conserved in the neurons of cultured mice and human cells. What about the orthologs of these epigenetic proteins in humans? A review of the databases shows that expression by human orthologs of the two proteins mentioned above, BAZ2B and EHMT1, increases with age and is positively correlated with the progression of Alzheimer's disease. Researchers have verified that ablation of BAZ-2 mouse ortholog Baz2b attenuates age-dependent body weight gain and prevents cognitive decline in aging mice.

enter image description here While wild-type mice grew fat with age, animals lacking both copies of the epigenetic reader Baz2b stayed trim, indicating improved mitochondrial function. [Yuan et al., Nature, 2020.]

However, it must be asked whether BAZ-2 and SET-6 would rather mediate age-related physiological adaptation, rather than the agents of aging itself. Indeed their action could reflect a mechanism of adaptation to a progressively more hostile biological environment.

Significance of the Topic

The topic of this text revolves around understanding the molecular mechanisms underlying the genetic risks associated with Alzheimer's disease (Alzheimer's disease) conferred by the Apolipoprotein E (APOE) gene. Specifically, it explores the role of the 4 and 2 alleles of the APOE gene in modulating Alzheimer's disease pathology. The significance of this topic lies in its potential to shed light on the underlying biology of Alzheimer's disease, a complex and multifactorial disease.

Importance

Alzheimer's disease is a devastating and debilitating neurodegenerative disorder that affects millions of people worldwide. Understanding the genetic and molecular mechanisms underlying Alzheimer's disease is crucial for developing effective therapeutic strategies and preventing or slowing disease progression. The APOE gene has been associated with Alzheimer's disease risk, with the 4 allele being a well-established risk factor.

However, the underlying molecular mechanisms remain poorly characterized, making this research area highly important and timely.

Timeliness

The text is timely as it addresses a critical knowledge gap in the field of Alzheimer's disease research. Recent advances in proteomics and genomics have enabled researchers to systematically profile APOE-associated proteomic alterations in human samples, providing new insights into the molecular mechanisms underlying Alzheimer's disease. The text leverages these advances to investigate the role of the APOE 4 and 2 alleles in Alzheimer's disease pathology, making it a timely contribution to the field.

Relevance

The text has significant relevance to Alzheimer's disease research, as it provides novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The findings have implications for the development of therapeutic strategies for early intervention and potentially for the identification of new targets for Alzheimer's disease treatment.

Furthermore, the text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease, rather than just focusing on the 4 allele.

Analysis of the Text

The text presents a comprehensive analysis of APOE-associated proteomic alterations across five cohorts, using a range of proteomics platforms and samples, including plasma and cerebrospinal fluid (cerebrospinal fluid). The study uses systematic profiling to identify a comprehensive APOE-protein network and applies mediation modeling to classify genotype-related signals as upstream mediators, downstream consequences, or APOE-specific changes. The text then leverages cerebrospinal fluid beta-amyloid (A ) biomarker data to improve temporal resolution and isolate early, A -independent proteomic programs.

The findings of the text are significant, as they provide novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology. The study identifies allele-specific, temporally structured proteomic signatures that precede Alzheimer's disease pathology, offering potential therapeutic targets for early intervention. The text highlights the importance of considering the APOE 4 and 2 alleles as distinct risk factors for Alzheimer's disease and underscores the challenges in reproducibility associated with proteomics studies.

Usefulness for Disease Management and Drug Discovery

The text provides valuable insights for Alzheimer's disease disease management and drug discovery, as it highlights the potential therapeutic targets for early intervention. The identification of allele-specific, temporally structured proteomic signatures offers a new perspective on Alzheimer's disease pathology and provides a starting point for the development of novel therapeutic strategies. The text also underscores the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk, which may inform personalized medicine approaches.

Original Information Beyond the Obvious

While the text presents novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology, it does not break new ground in terms of fundamental understanding.

However, the systematic profiling and mediation modeling approaches used in the study provide a comprehensive and nuanced understanding of APOE-associated proteomic alterations, which is a significant advance in the field. The text highlights the challenges associated with reproducibility in proteomics studies, emphasizing the need for careful consideration of sample size, platform choice, and data analysis methods.

Overall, the text provides a comprehensive and insightful analysis of APOE-associated proteomic alterations in human samples, highlighting the importance of considering individual variability in APOE genotype as a critical factor in Alzheimer's disease risk. The findings offer novel insights into the molecular mechanisms underlying APOE-driven Alzheimer's disease pathology and provide potential therapeutic targets for early intervention.

Read the original article on medRxiv

title_4

- Posted by system in English

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text presents a study investigating the use of serum neurofilament light chain (NfL) as a biomarker for neurodegeneration in patients with idiopathic Parkinson's Disease (iPD) and those carrying the p.A53T mutation in the SNCA gene, commonly known as A53T-PD. This topic is significant in the field of neurodegenerative diseases, particularly Parkinson's Disease (PD), as it has the potential to aid in the development of disease-modifying treatments (DMTs) for A53T-PD.

Importance

The importance of this study lies in its potential to provide a more accurate and early diagnosis of A53T-PD, which is a severe and rapidly progressing form of PD. By using serum NfL levels as a biomarker, clinicians can potentially identify patients carrying the p.A53T mutation earlier in the disease process, enabling them to design and implement targeted treatments to slow disease progression.

Timeliness

The study is timely in the sense that researchers are increasingly focusing on developing biomarkers for PD to facilitate the development of DMTs. The Parkinson's Progression Markers Initiative (PPMI) is a prominent research program aimed at identifying biomarkers for PD progression. The study's findings contribute to this research effort, providing valuable insights into the use of serum NfL levels as a biomarker for A53T-PD.

Relevance

The study's findings are relevant to disease management and drug discovery in PD. The identification of A53T-PD as a distinct entity with a more aggressive neurodegenerative process than iPD has important implications for treatment strategies. By targeting the specific needs of patients with A53T-PD, clinicians may be able to slow disease progression and improve quality of life for this subset of patients.

Analysis of the Text: Relating Items

  • Serum NfL levels: Elevated serum NfL levels are a known marker of axonal damage and are associated with various neurodegenerative conditions.
  • A53T-PD: Patients with the p.A53T mutation in the SNCA gene experience a severe and rapidly progressing form of PD.
  • Idiopathic Parkinson's Disease (iPD): iPD is a complex and multifactorial disorder with an unclear etiology.
  • Parkinson's Progression Markers Initiative (PPMI): PPMI is a research program aimed at identifying biomarkers for PD progression.

The study's findings suggest that serum NfL levels are significantly higher in A53T-PD patients compared to iPD patients and healthy controls. This difference in serum NfL levels may be a valuable biomarker for identifying A53T-PD and designing targeted treatments to slow disease progression.

Usefulness of the Text for Disease Management or Drug Discovery

The study's findings have implications for disease management and drug discovery in PD. The identification of A53T-PD as a distinct entity with a more aggressive neurodegenerative process than iPD highlights the need for targeted treatments that address the specific needs of this subset of patients. By using serum NfL levels as a biomarker, clinicians may be able to identify patients with A53T-PD earlier in the disease process, enabling them to implement disease-modifying treatments (DMTs) to slow disease progression.

Originality of the Text

The study presents original information beyond the obvious in that it:

  • Investigates the use of serum NfL levels as a biomarker for A53T-PD, a specific and severe form of PD.
  • Compares serum NfL levels in A53T-PD patients to those with iPD and healthy controls.
  • Identifies serum NfL levels as a potential biomarker for A53T-PD, highlighting its potential for early diagnosis and targeted treatment.

However, the study's findings are not unexpected, as elevated serum NfL levels are a known marker of axonal damage in various neurodegenerative conditions. Nevertheless, the study's results contribute to the growing body of research on PD biomarkers and highlight the potential for targeted treatments in A53T-PD.

Read the original article on medRxiv

Analysis of the Text: Significance, Importance, Timeliness, and Relevance

The text presents a study on identifying distinct Alzheimer's disease subgroups using unsupervised learning techniques and electronic medical records from UCSF. The significance of this topic lies in its potential to improve our understanding of the disease's manifestations, management, and treatment.

Importance: Alzheimer's disease is a complex and debilitating condition affecting millions worldwide. The current understanding of the disease is limited, and existing treatments have shown limited success in reversing or halting its progression. Identifying distinct subgroups of the disease can help researchers and clinicians to develop targeted therapeutic approaches, leading to improved patient outcomes.

Timeliness: The study's focus on sex-stratified analyses is particularly timely, given the growing recognition of sex differences in Alzheimer's disease. The disease's female sex predominance is well-documented, but the reasons underlying this disparity are still not fully understood. This study's findings on sex-specific variations in disease manifestations can contribute to a better understanding of the biological factors involved.

Relevance: The study's relevance lies in its potential to inform individualized therapeutic regimens. By identifying distinct subgroups and sex-specific variations, clinicians may be able to tailor treatment approaches to specific patient needs, leading to more effective disease management.

Analysis of the Key Items:

  1. Unsupervised learning techniques: The use of unsupervised learning techniques allows for the identification of patterns and relationships in the data that may not be immediately apparent. This approach is particularly useful in complex data sets like electronic medical records.
  2. Electronic medical records: The study leverages electronic medical records from UCSF to identify distinct Alzheimer's disease subgroups. This approach has the potential to provide valuable insights into the disease's manifestations and management.
  3. Sex-stratified analyses: The study's focus on sex-stratified analyses is critical in understanding the underlying biological factors contributing to the disease's female sex predominance.
  4. Identification of Alzheimer's disease subphenotypes: The study identified five distinct Alzheimer's disease subphenotypes, characterized by comorbidities related to cardiovascular conditions, gastrointestinal disorders, and frailty-related conditions.
  5. Validation using an independent UC-Wide dataset: The study's findings were validated using an independent UC-Wide dataset, ensuring the robustness and generalizability of the results.

Usefulness for Disease Management and Drug Discovery:

The study's findings have the potential to inform individualized therapeutic regimens, leading to improved patient outcomes. The identification of distinct subgroups and sex-specific variations can help clinicians to develop targeted treatment approaches, tailoring care to specific patient needs.

Original Information Beyond the Obvious:

The study provides original information beyond the obvious by:

  1. Identifying distinct Alzheimer's disease subphenotypes: The study's findings contribute to our understanding of the disease's manifestations and management.
  2. Highlighting sex-specific variations: The study's focus on sex-stratified analyses sheds light on the underlying biological factors contributing to the disease's female sex predominance.
  3. Providing a framework for individualized therapeutic regimens: The study's findings have the potential to inform the development of targeted treatment approaches, improving patient outcomes.

Overall, the study presents a valuable contribution to the field of Alzheimer's disease research, highlighting the importance of identifying distinct subgroups and sex-specific variations in disease manifestations.

Read the original article on medRxiv


Please, help us continue to provide valuable information: